Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma

Haematologica

Volumn 95, Issue 10, 2010, Pages 1691-1696

  Hines Thomas, Melissa R ^a   Howard, Scott C ^a,b   Hudson, Melissa M ^a,b   Krasin, Matthew J ^b   Kaste, Sue C ^a,b   Shulkin, Barry L ^b   Metzger, Monika L ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Bone marrow; Hodgkin's lymphoma; Risk features

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE DISEASE; BONE MARROW; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CHILD; CLASSICAL HODGKIN LYMPHOMA; DISEASE FREE SURVIVAL; HODGKIN DISEASE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; LYMPHADENOPATHY; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE MARROW EXAMINATION; CHILD; CHILD, PRESCHOOL; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 77957808680     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.025072     Document Type: Article

References (38)

1. th ed: Churchill Livingstone 2009.
2. Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1995;13(2):403-409.
3. Abrahamsen AF, Jakobsen E, Langholm R, Abrahamsen JF, Kvaloy S, Nome O. Bone marrow examination in Hodgkin's disease. Acta Oncol. 1992;31(1):41-42.
4. Howell SJ, Grey M, Chang J, Morgenstern GR, Cowan RA, Deakin DP, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol. 2002;119(2):408-411.
5. Marcus RH, Weinert L, Neumann A, Borow KM, Lang RM. Venous air embolism. Diagnosis by spontaneous right-sided contrast echocardiography. Chest. 1991;99(3): 784-785.
6. Spector N, Nucci M, Oliveira De Morais JC, Maiolino A, Portugal RD, Costa MA, et al. Clinical factors predictive of bone marrow involvement in Hodgkin's disease. Leuk Lymphoma. 1997;26(1-2):171-176.
7. Simpson CD, Gao J, Fernandez CV, Yhap M, Price VE, Berman JN. Routine bone marrow examination in the initial evaluation of paediatric Hodgkin lymphoma: the Canadian perspective. Br J Haematol. 2008;141(6):820-826.
8. Mahoney DH, Jr., Schreuders LC, Gresik MV, McClain KL. Role of staging bone marrow examination in children with Hodgkin disease. Med Pediatr Oncol. 1998;30(3):175-177.
9. Barros MH, Zalcberg IR, Hassan R. Clinical and laboratorial prediction of bone marrow involvement in children and adolescents with Hodgkin lymphoma. Pediatr Blood Cancer. 2008;50(4):765-768.
10. Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood. 2005;105(5): 1875-1880.
11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11): 1860-1861.
12. Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, earlystage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20(14): 3081-3087.
13. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630-637.
14. Hudson MM, Greenwald C, Thompson E, Wilimas J, Marina N, Fairclough D, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol. 1993;11(1): 100-108.
15. Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involvedfield radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol. 2004;22 (22):4541-4550.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Bartl R, Frisch B, Burkhardt R, Huhn D, Pappenberger R. Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. Br J Haematol. 1982; 51(3):345-360.
18. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339(21):1506-1514.
19. Rosenberg SA. Hodgkin's disease of the bone marrow. Cancer Res. 1971;31(11): 1733-1736.
20. Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol. 1988;41(4):359-367.
21. Bennett JM, Gralnick HR, Devita VT, Jr. Bonemarrow biopsy in Hodgkin's disease. N Engl J Med. 1968;278(21):1179.
22. Macintyre EA, Vaughan Hudson B, Linch DC, Vaughan Hudson G, Jelliffe AM. The value of staging bone marrow trephine biopsy in Hodgkin's disease. Eur J Haematol. 1987;39(1):66-70.
23. Gobbi PG, Comelli M, Grignani GE, Pieresca C, Bertoloni D, Ascari E. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica. 1994;79(3):241-255.
24. Maucort-Boulch D, Djeridane M, Roy P, Riche B, Colonna P, Andrieu JM. Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer. 2007;109(2):256-264.
25. Ostrowski ML, Inwards CY, Strickler JG, Witzig TE, Wenger DE, Unni KK. Osseous Hodgkin disease. Cancer. 1999;85(5):1166-1178.
26. Feltl D, Markova J, Mocikova H, Dedeckova K, Kozak T. Prognostic impact of bone involvement in Hodgkin lymphoma. Neoplasma. 2008;55(2):96-100.
27. Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M, et al. Isolated parenchymal lung involvement in children with stage IV Hodgkin's disease: results of the UKCCSG HD8201 and HD9201 studies. Br J Haematol. 2002;119(2):441-444.
28. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-Ffluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998; 16(2):603-609.
29. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, et al. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging. 2008;52(1):9-16.
30. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, et al. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006;28(6):362-368.
31. Weiner MA, Leventhal BG, Marcus R, Brecher M, Ternberg J, Behm FG, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1991;9(9):1591-159.
32. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, et al. Randomized study of intensive MOPPABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997;15(8):2769-2779.
33. Tebbi CK, Mendenhall N, London WB, Williams JL, de Alarcon PA, Chauvenet AR. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer. 2006; 46(2):198-202.
34. Fryer CJ, Hutchinson RJ, Krailo M, Collins RD, Constine LS, Hays DM, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group. J Clin Oncol. 1990;8(12):1971-1980.
35. Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group phase III trial. J Clin Oncol. 1998;16(3):897-906.
36. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18): 3765-3771.
37. Korholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F, et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr. 2004;216(3):150-156.
38. Ruhl U, Albrecht M, Dieckmann K, Luders H, Marciniak H, Schellenberg D, et al. Responseadapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51(5):1209-1218.